{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:24:11Z","timestamp":1793665451455,"version":"4.5.1"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["704121"],"award-info":[{"award-number":["704121"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["419699"],"award-info":[{"award-number":["419699"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite the curative potential of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia (AML), its efficacy is limited by intrinsic resistance of cancer cells to donor-derived T-cell cytotoxicity. Using a genome-wide CRISPR screen, we identified the SOCS1\u2013JAK1\u2013STAT1 pathway as a mediator of AML susceptibility to T cells. Knockdown of SOCS1 in AML cells sensitized them to killing by allogeneic T cells, whereas SOCS1 overexpression in AML cells induced resistance to T-cell antileukemic activity. Mechanistically, SOCS1 protected AML cells from T-cell killing by antagonizing IFN\u03b3\u2013JAK1\u2014induced ICAM-1 expression. Furthermore, primary AML cells with lower SOCS1 expression correlated with better overall survival in patients, especially those with a lower exhausted CD8+ T-cell score. Thus, this study reveals SOCS1 and its downstream mediators as a potential targetable pathway to enhance T cell\u2013based immunotherapy for AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our investigation of the SOCS1 pathway in AML and T-cell interactions provides insights into potential mechanisms of resistance of AML to allogeneic hematopoietic stem cell transplantation and demonstrates the potential of targeting SOCS1 and its downstream mediators to enhance antileukemic T-cell activity.<\/jats:p>\n                    <jats:p>See related commentary by Fry, p. 157.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0140","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T14:08:26Z","timestamp":1739196506000},"page":"217-232","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["SOCS1 Protects Acute Myeloid Leukemia against Allogeneic T Cell\u2013Mediated Cytotoxicity"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7838-0400","authenticated-orcid":false,"given":"Enoch","family":"Tin","sequence":"first","affiliation":[{"name":"1Toronto General Hospital Research Institute, University Health Network, Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-7375","authenticated-orcid":false,"given":"Sergio","family":"Rutella","sequence":"additional","affiliation":[{"name":"3John van Geest Cancer Research Center, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0571-4749","authenticated-orcid":false,"given":"Ismat","family":"Khatri","sequence":"additional","affiliation":[{"name":"1Toronto General Hospital Research Institute, University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2319-0293","authenticated-orcid":false,"given":"Yoosu","family":"Na","sequence":"additional","affiliation":[{"name":"1Toronto General Hospital Research Institute, University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7337-4331","authenticated-orcid":false,"given":"Yongran","family":"Yan","sequence":"additional","affiliation":[{"name":"4Princess Margaret Cancer Centre, University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2642-6079","authenticated-orcid":false,"given":"Neil","family":"MacLean","sequence":"additional","affiliation":[{"name":"4Princess Margaret Cancer Centre, University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2671-4285","authenticated-orcid":false,"given":"Jayakumar","family":"Vadakekolathu","sequence":"additional","affiliation":[{"name":"3John van Geest Cancer Research Center, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9089-8816","authenticated-orcid":false,"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[{"name":"4Princess Margaret Cancer Centre, University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-3899","authenticated-orcid":false,"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[{"name":"4Princess Margaret Cancer Centre, University Health Network, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4744-6021","authenticated-orcid":false,"given":"JongBok","family":"Lee","sequence":"additional","affiliation":[{"name":"1Toronto General Hospital Research Institute, University Health Network, Toronto, Canada."},{"name":"5Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-0757","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Toronto General Hospital Research Institute, University Health Network, Toronto, Canada."},{"name":"2Department of Immunology, University of Toronto, Toronto, Canada."},{"name":"6Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2026041309335463000_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2026041309335463000_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"2026041309335463000_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.blre.2019.02.001","article-title":"Cellular immunotherapy for acute myeloid leukemia: how specific should it be?","volume":"35","author":"Lee","year":"2019","journal-title":"Blood Rev"},{"key":"2026041309335463000_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"key":"2026041309335463000_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"2026041309335463000_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"2026041309335463000_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-17-2228","article-title":"Allogeneic human double negative t cells as a novel immunotherapy for acute myeloid leukemia and its underlying mechanisms","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026041309335463000_bib8","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1158\/1078-0432.CCR-18-2291","article-title":"Developing allogeneic double-negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026041309335463000_bib9","doi-asserted-by":"crossref","first-page":"E264","DOI":"10.1002\/ajh.26564","article-title":"Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: a first-in-human phase I study","volume":"97","author":"Tang","year":"2022","journal-title":"Am J Hematol"},{"key":"2026041309335463000_bib10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026041309335463000_bib11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK\u2013STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"2026041309335463000_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of JAK\/STAT inhibition by SOCS1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun"},{"key":"2026041309335463000_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ng0501-29","article-title":"SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity","volume":"28","author":"Yoshikawa","year":"2001","journal-title":"Nat Genet"},{"key":"2026041309335463000_bib14","first-page":"1008","article-title":"Association between methylation of tumor suppressor gene SOCS1 and acute myeloid leukemia","volume":"40","author":"Zhang","year":"2018","journal-title":"Oncol Rep"},{"key":"2026041309335463000_bib15","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1038\/bcj.2017.67","article-title":"Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia","volume":"7","author":"Hou","year":"2017","journal-title":"Blood Cancer J"},{"key":"2026041309335463000_bib16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2010-08-301416","article-title":"SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control","volume":"120","author":"Reddy","year":"2012","journal-title":"Blood"},{"key":"2026041309335463000_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-023-01929-1","article-title":"JAK\/STAT in leukemia: a clinical update","volume":"23","author":"Liang","year":"2024","journal-title":"Mol Cancer"},{"key":"2026041309335463000_bib18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clml.2022.01.012","article-title":"A phase 1\/2 study of the oral Janus kinase 1 inhibitors INCB052793 and itacitinib alone or in combination with standard therapies for advanced hematologic malignancies","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041309335463000_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","article-title":"A phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia","volume":"15","author":"Pemmaraju","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041309335463000_bib20","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2011-12-400051","article-title":"Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia","volume":"119","author":"Eghtedar","year":"2012","journal-title":"Blood"},{"key":"2026041309335463000_bib21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"},{"key":"2026041309335463000_bib22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.2019004108","article-title":"CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy","volume":"137","author":"Soares","year":"2021","journal-title":"Blood"},{"key":"2026041309335463000_bib23","unstructured":"NCI\n          . CAR T cells: engineering immune cells to treat cancer - NCI. 2022. [cited 2023 Feb 11]. Available from:https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells."},{"key":"2026041309335463000_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2026041309335463000_bib25","first-page":"13","article-title":"Tumor necrosis factor alpha (TNF-alpha) activates Jak1\/Stat3-Stat5b signaling through TNFR-1 in human B cells","volume":"13","author":"Miscia","year":"2002","journal-title":"Cell Growth Differ"},{"key":"2026041309335463000_bib26","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1182\/bloodadvances.2023011739","article-title":"Double-negative T cells utilize a TNF\u03b1\u2013JAK1\u2013ICAM-1 cytotoxic axis against acute myeloid leukemia","volume":"8","author":"Tin","year":"2024","journal-title":"Blood Adv"},{"key":"2026041309335463000_bib27","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41375-024-02255-1","article-title":"AML\/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML","volume":"38","author":"Sayitoglu","year":"2024","journal-title":"Leukemia"},{"key":"2026041309335463000_bib28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2021.12.039","article-title":"Magnesium sensing via LFA-1 regulates CD8+ T cell effector function","volume":"185","author":"L\u00f6tscher","year":"2022","journal-title":"Cell"},{"key":"2026041309335463000_bib29","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1038\/s41467-022-30809-3","article-title":"Mechanically active integrins target lytic secretion at the immune synapse to facilitate cellular cytotoxicity","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"2026041309335463000_bib30","doi-asserted-by":"crossref","first-page":"12242","DOI":"10.1038\/ncomms12242","article-title":"A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion","volume":"7","author":"Petit","year":"2016","journal-title":"Nat Commun"},{"key":"2026041309335463000_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/cancers9110153","article-title":"Role of LFA-1 and ICAM-1 in cancer","volume":"9","author":"Reina","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2026041309335463000_bib32","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"2026041309335463000_bib33","doi-asserted-by":"crossref","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026041309335463000_bib34","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041309335463000_bib35","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"key":"2026041309335463000_bib36","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"2026041309335463000_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","article-title":"Functional genomic landscape of cancer-intrinsic evasion of killing by T cells","volume":"586","author":"Lawson","year":"2020","journal-title":"Nature"},{"key":"2026041309335463000_bib38","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1038\/s41467-023-43790-2","article-title":"Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening","volume":"14","author":"Ramos","year":"2023","journal-title":"Nat Commun"},{"key":"2026041309335463000_bib39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41419-018-0812-6","article-title":"CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis"},{"key":"2026041309335463000_bib40","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1916206117","article-title":"Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia","volume":"117","author":"Lamble","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026041309335463000_bib41","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.2023021680","article-title":"CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia","volume":"144","author":"Mazziotta","year":"2024","journal-title":"Blood"},{"key":"2026041309335463000_bib42","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2009-02-206946","article-title":"Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts","volume":"114","author":"Le Dieu","year":"2009","journal-title":"Blood"},{"key":"2026041309335463000_bib43","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1158\/2326-6066.CIR-20-0837","article-title":"CAR T-cell entry into tumor islets is a two-step process dependent on IFN\u03b3 and ICAM-1","volume":"9","author":"Kantari-Mimoun","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2026041309335463000_bib44","doi-asserted-by":"crossref","first-page":"eabl3642","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci Immunol"},{"key":"2026041309335463000_bib45","doi-asserted-by":"crossref","first-page":"e007277","DOI":"10.1136\/jitc-2023-007277","article-title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","volume":"11","author":"Fang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026041309335463000_bib46","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-15-2743","article-title":"An integrated analysis of heterogeneous drug responses in acute myeloid leukemia that enables the discovery of predictive biomarkers","volume":"76","author":"Chen","year":"2016","journal-title":"Cancer Res"},{"key":"2026041309335463000_bib47","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1038\/s41598-022-12449-1","article-title":"SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis","volume":"12","author":"Song","year":"2022","journal-title":"Sci Rep"},{"key":"2026041309335463000_bib48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"2026041309335463000_bib49","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","article-title":"High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities","volume":"163","author":"Hart","year":"2015","journal-title":"Cell"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0140\/3540613\/bcd-24-0140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0140\/3563477\/bcd-24-0140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/217\/3601278\/bcd-24-0140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/3\/217\/3601278\/bcd-24-0140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:34:13Z","timestamp":1776087253000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/3\/217\/762118\/SOCS1-Protects-Acute-Myeloid-Leukemia-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,10]]},"published-print":{"date-parts":[[2025,5,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0140","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7801751","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.28929671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929680","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.28929683","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}